Cost-effectiveness claims tend to assume mortality benefit, study finds

A new study has found that published cost-effectiveness claims related to cardiovascular therapies tend to assume a mortality benefit, without clear support from gold standard clinical trial data.

The cost-effectiveness analysis is an important tool for assessing the costs and clinical outcomes of an innovation, and is used to support market access and pricing discussions.

Conducted by the Partnership for Health Analytic Research, the study found that, due to a lack of available data on mortality, 88% of such papers did not use direct, statistically significant randomized controlled trial evidence to support the mortality benefit.